Research Topics
Genomes and Genes | WILLIAM A contact WEISSSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cellsJoachim Silber
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
BMC Med 6:14. 2008..In this study, we investigated the role of microRNAs in regulating the differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells...
Can mouse models for brain tumors inform treatment in pediatric patients?William A Weiss
Departments of Neurology, Pediatrics, and Neurological Surgery, University of California, San Francisco, CA 94143, USA
Semin Cancer Biol 14:71-7. 2004..Mouse models for brain tumors may help to identify targeted agents, and combinations of agents, effective against these tumors. Such data can be used to prioritize therapies for clinical trials in children with these tumors...- Recognizing and exploiting differences between RNAi and small-molecule inhibitorsWilliam A Weiss
University of California, 533 Parnassus Avenue, San Francisco, California 94143, USA
Nat Chem Biol 3:739-44. 2007 - Genome-wide screen for allelic imbalance in a mouse model for neuroblastomaW A Weiss
Department of Neurology, University of California, San Francisco 94143 0114, USA
Cancer Res 60:2483-7. 2000.... - Neuropathology of genetically engineered mice: consensus report and recommendations from an international forumWilliam A Weiss
Department of Neurology, University of California, 521 Parnassus Avenue, San Francisco, California, CA 94143 0114, USA
Oncogene 21:7453-63. 2002..Recommendations were also made for preclinical validation of these models in cancer therapeutics, and for incorporation of surrogate markers of tumor burden to facilitate preclinical evaluation of new therapies... - Genetics of brain tumorsW A Weiss
Department of Neurology, University of California, San Francisco 94143 0114, USA
Curr Opin Pediatr 12:543-8. 2000..Further studies are needed to identify genetic alterations in pilocytic and low-grade astrocytomas, which account for 40% of brain tumors in children... - Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approachQi-Wen Fan
Department of Neurology, University of California, San Francisco, California 94143-0663, USA
Cancer Res 63:8930-8. 2003..Our experiments provide a preclinical mechanistic basis for combining biologically based therapies directed against two targets within a complex signaling cascade... - Genetic determinants of malignancy in a mouse model for oligodendrogliomaWilliam A Weiss
Department of Neurology, University of California, San Francisco, California 94143 0663, USA
Cancer Res 63:1589-95. 2003..These models hold promise for studying tumor lineage, identifying contributing genetic alterations and evaluating preclinical therapies in this important neoplasm... - EGFR signals to mTOR through PKC and independently of Akt in gliomaQi Wen Fan
Department of Neurology, University of California, 533 Parnassus Avenue, San Francisco, CA 94143, USA
Sci Signal 2:ra4. 2009..These findings underline the importance of signaling between EGFR and mTOR in glioma, identify PKCalpha as essential to this network, and question the necessity of Akt as a critical intermediate coupling EGFR and mTOR in glioma... - RNA interference against a glioma-derived allele of EGFR induces blockade at G2MQi Wen Fan
Department of Neurology, University of California, San Francisco, CA 94143 0663, USA
Oncogene 24:829-37. 2005.... - Pleiotropic role for MYCN in medulloblastomaFredrik J Swartling
University of California at San Francisco, San Francisco, California 94158, USA
Genes Dev 24:1059-72. 2010..Targeted expression of MYCN thus contributes to initiation, progression, and maintenance of MB, suggesting a central role for MYCN in pathogenesis... - Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8Chibo Hong
Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, California 94143 0875, USA
Cancer Res 65:3617-23. 2005..The shared epigenetic inactivation of mSLC5A8 in mouse gliomas indicates an additional degree of commonality in the origin and/or pathway to tumorigenesis between primary human tumors and these mouse models of gliomas... 
The side story of stem-like glioma cellsAnders I Persson
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
Cell Stem Cell 4:191-2. 2009..Surprisingly, temozolomide, the first-line chemotherapeutic used for treatment of glioma, increased this side population, and even more so when PTEN was deleted...- PI3K signaling in glioma--animal models and therapeutic challengesChristine K Cheng
Department of Neurology, University of California, San Francisco, CA 94143, USA
Brain Pathol 19:112-20. 2009..The engagement of other survival pathways in response to PI3K inhibition prompts the need to develop combination therapies that promote cytotoxicity in cancer cells... - Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarityWei Yu
Department of Anatomy, Neurology, University of California, San Francisco, California 94143, USA
EMBO Rep 9:923-9. 2008..These results might be relevant to the hyperactivation of RhoA and disruption of normal polarity frequently observed in human epithelial cancers... - A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant gliomaQi Wen Fan
Department of Neurology and Brain Tumor Research Center, Comprehensive Cancer Center, Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA
Cancer Res 67:7960-5. 2007..These experiments show that a dual inhibitor of PI3Kalpha and mTOR augments the activity of EGFR blockade, offering a mechanistic rationale for targeting EGFR, PI3Kalpha, and mTOR in the treatment of EGFR-driven, PTEN-mutant glioma... - Isoform specific inhibitors of PI3 kinase in gliomaQi-Wen Fan
Department of Neurology, Pediatrics, Neurological Surgery, and Brain Tumor Research Center, Comprehensive Cancer Center, San Francisco, California 94143, USA
Cell Cycle 5:2301-5. 2006..This result suggests a potentially effective strategy for cancer therapy based on dual inhibition of these two PI3K family members... - Childhood tumors of the nervous system as disorders of normal developmentMatthew R Grimmer
Department of Neurology, University of California, San Francisco, CA 94143, USA
Curr Opin Pediatr 18:634-8. 2006..We provide a detailed discussion of two pediatric neural tumors, medulloblastoma and neuroblastoma, addressing tumorigenic causality and similarities within a pharmacological context... - A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaQi-Wen Fan
Department of Neurology, University of California, San Francisco, San Francisco, California 94143, USA
Cancer Cell 9:341-9. 2006..PI-103 showed significant activity in xenografted tumors with no observable toxicity. These data demonstrate an emergent efficacy due to combinatorial inhibition of mTOR and PI3 kinase alpha in malignant glioma... - Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastomaLouis Chesler
Department of Neurology, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
Cancer Res 66:8139-46. 2006.... - Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug deliveryDennis J Yoon
Department of Bioengineering, University of California, Los Angeles, CA 90095, USA
Cancer Res 70:4520-7. 2010..Treatment of GBM xenografts with mutant Tf-conjugated DT resulted in pronounced regression in vivo, indicating their potential use as drug carriers... - Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 inductionLouis Chesler
Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
Neoplasia 10:1268-74. 2008.... - Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumorsChristopher S Hackett
Department of Neurology, University of California, San Francisco, California 94143-0114, USA
Cancer Res 63:5266-73. 2003..These data demonstrate conservation of many genetic changes in murine and human neuroblastoma and suggest that further delineation of genetic abnormalities in murine tumors may identify genes important in human disease... - Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signalingQi-Wen Fan
Department of Neurology, University of California, San Francisco, CA 94143, USA
Curr Biol 12:1386-94. 2002..CONCLUSIONS: These data suggest that mammalian cells can become dependent on aberrant oncogenic signaling; this dependency renders them incapable of returning to a normal, proliferative phenotype... - Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastomaLouis Chesler
Department of Pediatrics, Neurology, University of California San Francisco Medical School, San Francisco, California 94143, USA
Cancer Res 67:9435-42. 2007.... - Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cellsGary E Meyer
Department of Pediatrics, University of California, San Francisco, California 94143, USA
J Cell Biochem 102:1529-41. 2007..In addition, NDGA inhibits the growth of xenografted human neuroblastoma tumors in nude mice. These results indicate that NDGA may be useful in the treatment of neuroblastoma and may function in part via disruption of IGF-IR signaling... - Structure-guided development of affinity probes for tyrosine kinases using chemical geneticsJimmy A Blair
Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, USA
Nat Chem Biol 3:229-38. 2007.... - A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signalingZachary A Knight
Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA
Cell 125:733-47. 2006..These results illustrate systematic target validation using a matrix of inhibitors that span a protein family... - Chemical genetic approaches to the development of cancer therapeuticsQi-Wen Fan
Department of Neurology, 533 Parnassus Avenue, San Francisco, CA 94143, USA
Curr Opin Genet Dev 16:85-91. 2006..Elucidation of the mechanisms through which specific small molecule drug-like agents impact crucial cancer pathways should yield important and clinically translatable insights into the use of similar agents in patients... - Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3Tsui Ting Ching
The Brain Tumor Research Center, Department of Neurological Surgery and the Biomedical Sciences Program, University of California San Francisco, San Franciso, California 94143, USA
Nat Genet 37:645-51. 2005..Defects in SHANK3 seem to underlie human 22q13 deletion syndrome. Furthermore, these patterns for SHANK3 are conserved in mice and rats... - BMPs oppose Math1 in cerebellar development and in medulloblastomaMatthew R Grimmer
Department of Neurology, University of California at San Francisco, San Francisco, California 94143, USA
Genes Dev 22:693-9. 2008 - Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastomaCatherine A Burkhart
Children's Cancer Institute Australia for Medical Research, Sydney, Australia
J Natl Cancer Inst 95:1394-403. 2003..Antisense strategies targeting the hMYCN oncogene in vivo decrease mouse neuroblastoma tumorigenesis. Investigation of their clinical effect in children with neuroblastoma is warranted... - Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastomaAndy J Cheng
Children s Cancer Institute Australia for Medical Research, P O Box 81, Randwick, 2031 Sydney, Australia
Eur J Cancer 43:1467-75. 2007..These isogenic lines together with the transgenic mice thus represent valuable models for investigating the biological characteristics of aggressive neuroblastoma... - Brain tumors in S100beta-v-erbB transgenic ratsHiroko Ohgaki
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
J Neuropathol Exp Neurol 65:1111-7. 2006.... - Genotype-phenotype correlations in tuberous sclerosis: who and how to treatSuzanne Goh
Ann Neurol 60:505-7. 2006 - Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplificationLoen M Hansford
Children s Cancer Institute Australia for Medical Research, Randwick 2031, Australia
Proc Natl Acad Sci U S A 101:12664-9. 2004..Our studies provide a model for studying perinatal factors influencing embryonal tumor initiation...
Research Grants
- Murine neuroblastoma models for preclinical therapeuticsWilliam Weiss; Fiscal Year: 2007..Aim 3 evaluates a role for MYCN in maintaining angiogenesis in murine neuroblastoma, determines how therapies that disrupt Mycn impact this process, and evaluates the importance of p53 in effectiveness of anti-angiogenic therapies. ..
- Murine neuroblastoma models for preclinical therapeuticsWilliam A Weiss; Fiscal Year: 2010..Aim 3 evaluates a role for MYCN in maintaining angiogenesis in murine neuroblastoma, determines how therapies that disrupt Mycn impact this process, and evaluates the importance of p53 in effectiveness of anti-angiogenic therapies. ..
- Medulloblastoma and MetastasesWILLIAM A contact WEISS; Fiscal Year: 2010..Successful completion of this proposal identifies metastases genes and new therapeutic targets for children with metastatic MB. ..
- Mycn and MedulloblastomaWilliam A Weiss; Fiscal Year: 2010..This study will clarify the importance of Mycn as a therapeutic target in medulloblastoma, and will evaluate a Mycn inhibitor that could potentially be translated to children with this important tumor. ..
- Modifiers of Tumor Susceptibility in Murine NeuroblastomaWilliam A Weiss; Fiscal Year: 2010..Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets. ..
- Imaging Kinase Activity In VivoWilliam Weiss; Fiscal Year: 2006....
- Murine neuroblastoma models for preclinical therapeuticsWilliam Weiss; Fiscal Year: 2005..Successful completion of this aim should lead to an efficient mechanism to better characterize mechanisms, and to ascertain the preclinical efficacy of combination and continuous low dose therapies. ..
- GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMAWilliam Weiss; Fiscal Year: 2004..Given the poor outcome associated with childhood neuroblastoma, this work has the potential to increase our understanding of the pathogenesis of neuroblastoma, and may result in improved therapies for children with this disorder. ..
- Modifiers of Tumor Susceptibility in Murine NeuroblastomaWilliam A Weiss; Fiscal Year: 2011..Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets. ..